Biomarkers For Psychiatric Disorders

This volume addresses one of the Holy Grails in Psychiatry, namely the evidence for and potential to adopt ‘Biomarkers’ for prevention, diagnosis, and treatment responses in mental health conditions. It meshes together state of the art research from international renowned pre-clinical and clinical scientists to illustrate how the fields of anxiety disorders, depression, psychotic disorders, and autism spectrum disorder have advanced in recent years.

Biomarkers of Postpartum Psychiatric Disorders provides an up-to-date reference on the current research relating to biomarkers in psychiatric disorders, including major depressive disorder, OCD and bipolar disorder in the immediate postpartum time-period. It is the only reference on the market that synthesizes and interprets available data and reviews clinical phenotypes. Topics cover hormonal contributions, immunology, epigenetics and neuroimaging. While the risk of psychiatric illness during pregnancy appears to be equivalent to the risk at any other time in a woman’s life, the risk in the immediate postpartum time period is dramatically increased, hence the importance of the discussions in this title. Identifies epigenetic, hormonal, immunological and neuroimaging biomarkers Provides biomarkers for depression, OCD and psychosis Includes clinical phenotypes for psychiatric disorders Discusses future research and directions in the field

Biomarkers hold immense promise for the early detection of disease. Unlike other disorders like diabetes and heart disease where a limited number of biological markers are at hand that allow the physician to come up with a reliable diagnosis, there are currently no such markers available for affective disorders. As in any other disease area a major goal is therefore the identification of early markers that can categorize subsets of subjects in a consistent manner. This will allow a more precise definition and categorization of affective disorders and in turn facilitate investigations of the pathogenesis of the diseases and enhance our ability for treatment. This edited volume will not only address the area of affective disorders but also other brain disorders that are neurological in nature, including Multiple Sclerosis and Alzheimer Disease.

Biomarkers hold immense promise for the early detection of disease. Unlike other disorders like diabetes and heart disease where a limited number of biological markers are at hand that allow the physician to come up with a reliable diagnosis, there are currently no such markers available for affective disorders. As in any other disease area a major goal is therefore the identification of early markers that can categorize subsets of subjects in a consistent manner. This will allow a more precise definition and categorization of affective disorders and in turn facilitate investigations of the pathogenesis of the diseases and enhance our ability for treatment. This edited volume will not only address the area of affective disorders but also other brain disorders that are neurological in nature, including Multiple Sclerosis and Alzheimer Disease.

Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia. Leading authors review state-of-the-art in their field of investigation and provide their views and perspectives for future research Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist

Personalized Psychiatry presents the first book to explore this novel field of biological psychiatry that covers both basic science research and its translational applications. The book conceptualizes personalized psychiatry and provides state-of-the-art knowledge on biological and neuroscience methodologies, all while integrating clinical phenomenology relevant to personalized psychiatry and discussing important principles and potential models. It is essential reading for advanced students and neuroscience and psychiatry researchers who are investigating the prevention and treatment of mental disorders. Combines neurobiology with basic science methodologies in genomics, epigenomics and transcriptomics Demonstrates how the statistical modeling of interacting biological and clinical information could transform the future of psychiatry Addresses fundamental questions and requirements for personalized psychiatry from a basic research and translational perspective

Employing accessible language throughout, this book covers the history of psychiatric research, the current state-of-the art in psychiatric practice, the physiological systems affected by psychiatric illnesses, the whole-body nature of these diseases and the impact that this aspect has on emerging biomarker discoveries. Further, it provides descriptions of the major specific psychiatric disorders and the special challenges regarding the diagnosis and treatment of each. The book concludes with insights into the latest developments in hand-held biomarker test devices, which can provide diagnostic information in less than 15 minutes in point-of-care settings. This book investigates the emerging use of biomarkers in the study of psychiatric diseases, a topic of considerable importance for a broad range of people including researchers, clinicians, psychiatrists, university students and even those whose lives are affected in some way by a psychiatric illness. The last category is hardly trivial, since a staggering one in three people worldwide show the criteria for at least one psychiatric disorder at some point in their lifetime.